Integer Holdings, a medical-device contract manufacturer, is the subject of a class action alleging it made false or misleading statements and omissions: that it overstated its competitive position in the electrophysiology (EP) manufacturing market; concealed sustained sales declines for two EP devices despite claiming demand visibility; and mischaracterized those devices as long-term growth drivers for its Cardio & Vascular segment. The complaint alleges that on October 23, 2025, Integer lowered its 2025 sales guidance below analysts’ estimates and projected 2026 net sales growth of -2% to 2% (organic 0%–4%). CEO Joseph W. Dziedzic allegedly said the company expects to return to 200 basis points above-market organic growth in 2027. The complaint further alleges Integer’s stock fell more than 32% on the disclosure.